Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024

Published 21/03/2024, 11:50
AGRX
-

Live Conference Call and Webcast at 8:30 a.m. ET

PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc.  (Nasdaq: NASDAQ:AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on  Thursday, March 28, 2024. Following the release, the Company will host a live conference call and webcast at  8:30 a.m. ET  to discuss the Company's financial results and provide a business update.

EventAgile Therapeutics Fourth Quarter & Full Year 2023 Financial Results Conference Call
DateThursday, March 28, 2024
Time8:30 a.m. ET / 5:30 a.m. PT


A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics website at  https://ir.agiletherapeutics.com/events-and-presentations. To participate in the live conference call via telephone, please register  here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call.

About Agile Therapeutics, Inc.
Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla ®, (levonorgestrel and ethinyl estradiol) transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion ®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com.  The Company may occasionally disseminate material, nonpublic information on the Company's website and LinkedIn account.

Contact:
Matt Riley

Head of Investor Relations & Corporate Communications

mriley@agiletherapeutics.com


Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.